Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Gains from Investment Securities (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Gains from Investment Securities for 6 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities rose 827.71% year-over-year to $1.5 million, compared with a TTM value of $10.9 million through Dec 2025, up 191.27%, and an annual FY2025 reading of $10.9 million, up 191.27% over the prior year.
  • Gains from Investment Securities was $1.5 million for Q4 2025 at Xeris Biopharma Holdings, up from $478000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $20.0 million in Q2 2023 and bottomed at -$416000.0 in Q2 2022.
  • Average Gains from Investment Securities over 5 years is $2.3 million, with a median of $447000.0 recorded in 2022.
  • The sharpest move saw Gains from Investment Securities tumbled 328.12% in 2021, then soared 4918.03% in 2023.
  • Year by year, Gains from Investment Securities stood at -$365000.0 in 2021, then skyrocketed by 292.88% to $704000.0 in 2022, then crashed by 93.04% to $49000.0 in 2023, then soared by 238.78% to $166000.0 in 2024, then surged by 827.71% to $1.5 million in 2025.
  • Business Quant data shows Gains from Investment Securities for XERS at $1.5 million in Q4 2025, $478000.0 in Q3 2025, and $860000.0 in Q2 2025.